Overview

Safety and Tolerability of Cilofexor in Participants With Primary Sclerosing Cholangitis (PSC) and Compensated Cirrhosis

Status:
Completed
Trial end date:
2021-09-02
Target enrollment:
Participant gender:
Summary
The primary objective of this study is to assess the safety and tolerability of escalating doses of cilofexor in participants with primary sclerosing cholangitis (PSC) and compensated cirrhosis.
Phase:
Phase 1
Details
Lead Sponsor:
Gilead Sciences